R&D Tax Credit
A dollar-for-dollar federal tax credit (IRC Section 41) that cuts what you owe by the amount of the credit for money spent developing or improving products, processes, software, formulas, or techniques.
The credit lives in Section 41, and most of the companies that qualify never claim it. You do not need a lab or a pharma pipeline. If your engineers are writing new software, your shop floor is reworking a production process, or you are building prototypes and testing materials to solve a problem you did not already know how to solve, that work likely counts. The legal test is whether you were resolving genuine technological uncertainty, not whether the work felt cutting-edge.
There are two ways to size the credit. The regular method is older and stingier on the base calculation; most companies run the Alternative Simplified Credit instead. ASC is 14% of your qualified research expenses above 50% of your average spend over the prior three years. If you had no qualifying spend in any of those three years, the rate drops to a flat 6% of current-year expenses. Qualified expenses are mostly wages for people doing or directly supervising the research, plus supplies and 65% of contractor costs.
If you are pre-revenue or barely profitable, the credit can still pay you. A qualified small business, defined as under $5 million in gross receipts for the year and within five years of its first gross receipts, can apply up to $500,000 of the credit against payroll taxes each year. The first $250,000 offsets the employer share of Social Security tax; anything left over hits the employer Medicare portion. That is real cash for a startup with no income tax bill to reduce.
The amortization mess is over. The 2017 tax law forced you to spread domestic R&D costs over five years starting in 2022, which gutted the deduction's timing value. The One Big Beautiful Bill Act, signed July 2025, created Section 174A and restored immediate expensing of domestic research costs for tax years beginning after December 31, 2024, and made it permanent. You deduct domestic R&D in the year you incur it again. Foreign research still gets amortized over 15 years, so where the work happens matters.
One deadline worth flagging: if you capitalized domestic R&D in 2022 through 2024 under the old rules, OBBBA lets you recover the unamortized balance, and eligible small businesses can amend those returns retroactively. The window to file those amended returns closes July 6, 2026 (or the statute of limitations for the year, if that comes first). The deduction and the credit are separate claims on the same spending, so coordinate them; expensing the cost does not stop you from also claiming the credit, but the credit reduces your deductible amount unless you make the Section 280C election.
Practical Example
A software company spends $400,000 on developer salaries that qualify as research expenses, and it had no qualifying R&D in the three prior years. Under the ASC special rate for first-time claimants, the credit is 6% of $400,000, or $24,000, which reduces federal tax owed dollar for dollar. If the same company had been spending on R&D in prior years (say a $300,000 trailing-three-year average), the base would be $150,000, the excess would be $250,000, and the 14% rate would yield a $35,000 credit. And because this is a pre-revenue startup under $5 million in gross receipts, it can take that credit against payroll taxes instead of waiting for an income tax bill.